- New offering provides an all-in-one AI platform optimized for
mammography, that seamlessly integrates artificial intelligence
(AI) applications from iCAD to aid clinicians in breast cancer
detection as well as breast density assessment and
notification.
Today GE HealthCare (Nasdaq: GEHC) announced the release of a
new, all-in-one platform of artificial intelligence (AI) apps to
support clinicians with breast cancer detection and improved
workflow productivity called MyBreastAI
Suite*. With this initial release, MyBreastAI Suite
integrates three AI applications from iCAD including ProFound AI
for DBT, SecondLook for 2D Mammography and PowerLook
Density Assessment to help support early detection and improve
patient outcomes, as well as help radiology departments improve
operational productivity.
As the global cancer burden rises, radiologists face increasing
challenges such as burnout, workforce attrition, and patient
backlogs, placing strain on and testing the resiliency of health
systems today. In ongoing efforts to combat breast cancer, the
healthcare community remains committed to early detection by
leveraging methods, like screening mammography, that have proven to
be effective in identifying early breast cancers and reducing
breast cancer-specific mortality.1 However, with breast cancer now
surpassing lung cancer as the most commonly diagnosed cancer
worldwide,2 clinicians are seeking tools that can address issues
related to access, burnout, variability, equity, and cost in breast
imaging to elevate and enhance the detection and diagnosis of
breast cancer.
The introduction of MyBreastAI Suite aims to address these
challenges by providing an all-in-one platform that can seamlessly
deploy AI to breast imaging workflow. With this initial release,
MyBreastAI Suite integrates three AI applications from iCAD’s
ProFound Breast Health Suite, including:
- ProFound AI for DBT: Trained with one of the largest
available 3D image datasets, ProFound AI for DBT provides
radiologists with crucial information, such as lesion Certainty of
Finding and Case Scores, which assists in prioritizing caseloads,
clinical decision-making, and may help reduce burnout.3
- SecondLook for 2D Mammography: The SecondLook
Computer-Aided Detection (CAD) system for mammography is intended
to identify and mark regions of interest on screening and
diagnostic mammograms from GE HealthCare’s full-field digital
mammography (FFDM) systems to bring them to the attention of the
radiologist after an initial reading has been completed.4
- PowerLook Density Assessment: This tool helps to
standardize breast density assessment and reduce variability across
multiple radiologists;5 simplify and standardize reporting and
stratification for clinicians;6and enables clinicians to provide
women with accurate and reliable breast density assessments based
on AI mammogram analysis.7
Studies show that the deployment of these digital solutions can
assist in prioritizing case load and clinical decision-making. For
example, iCAD reader study shows that radiologists reading with
ProFound AI for DBT increases reader sensitivity by 8%, increases
reader specificity by 6.9%8 and decreases reading time by up to 52%
compared to without.9
"As part of GE HealthCare’s ongoing commitment to transform
healthcare and improve patient outcomes, we continue to explore how
we can leverage the power of AI in mammography to support the early
detection of breast cancer,” says Pooja Pathak – Vice President and
General Manager of Mammography. “As screening guidelines continue
to evolve and more attention is given to personal risk factors such
as breast density, these kinds of tools are an important and
exciting addition to our comprehensive portfolio of breast imaging
technologies.”
“Through this new all-in-one AI platform designed to offer
radiologists enhanced clinical decision support and streamlined
workflows, clinicians will be able to deliver more timely, accurate
and personalized breast care in their practices today. We know that
early detection is key and AI solutions show great promise in
advancing breast cancer screening and transforming workflow for
radiologists,” says Mario Lois – General Manager of AI for Women’s
Health.
MyBreastAI Suite will first be available in the United States
and will be distributed, installed and supported by GE HealthCare
as part of the company’s Senographe Pristina mammography
portfolio.
This product may not be available in your country or region.
Please contact your GE HealthCare representative for more
information.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 100 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are an $18.3 billion
business with 50,000 employees working to create a world where
healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and
Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
_____________________________________________________
*MyBreastAI suite is a commercial offering that includes an AI
platform optimized for Mammography, ProFound AI for DBT, SecondLook
for 2D Mammography and PowerLook Density Assessment. These three
applications are provided by iCAD. MyBreastAI Suite is compatible
with the latest versions of iCAD, Inc. as of November 14, 2023.
1 https://www.ncbi.nlm.nih.gov/books/NBK222338/
2Bashar, MD Abu; Begam, Nazia1. Breast cancer surpasses lung
cancer as the most commonly diagnosed cancer worldwide. Indian
Journal of Cancer 59(3):p 438-439, Jul–Sep 2022. | DOI:
10.4103/ijc.IJC_83_21
3iCAD data on file. FDA filing: K203822. Standalone performance
varies by vendor. FDA Cleared and CE Mark Pending. Reading times
may vary based on the specific functionality of the viewing
application used for interpretation
4iCAD labelling and user manual, DTM 103 – Revision C.
5 iCAD labelling and user manuel, DTM103 – Revision C.
6iCAD labelling and user manual, DTM135-1, DTM156-3, DTM184
rev1.
7iCAD labelling and user manual, DTM135-1, DTM156-3, DTM184
rev1.
8 Reader performance with Profound AI compared to performance
without. iCAD reader study: Conant, E et al. (2019). Improving
Accuracy and Efficiency with Concurrent Use of Artificial
Intelligence for Digital Breast Tomosynthesis. Radiology:
Artificial Intelligence. 1 (4). Accessed via
https://pubs.rsna.org/doi/10.1148/ryai.2019180096. iCAD labelling
and user manual, DTM160 rev C.
9iCAD reader study: Conant, E et al. (2019). Improving Accuracy
and Efficiency with Concurrent Use of Artificial Intelligence for
Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1
(4). Accessed via
https://pubs.rsna.org/doi/10.1148/ryai.2019180096. iCAD labelling
and user manual, DTM160 rev C. Reading times may vary based on the
specific functionality of the viewing application used for
interpretation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231126633007/en/
Emily Dalton Niles Emily.niles@ge.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jul 2023 to Jul 2024